Date: 2012-01-17
Type of information: Production agreement
Compound: Reteplase (Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin® for thrombolytic treatment of myocardial infarction)
Company: Scil Proteins (Germany) Actavis (Switzerland)
Therapeutic area: Cardiovascular diseases
Type agreement: supply
Action mechanism:
Disease: myocardial infarction
Details: Scil Proteins,has signed a supply agreement with Actavis, a leading generic pharmaceutical company for the future manufacturing of Reteplase. Scil Proteins originally signed an agreement with Roche in June 2008 for process transfer and manufacture of Reteplase. Actavis owns rights on the Reteplase production process and on Rapilysin®for European and worldwide distribution excluding USA and Canada.
As well as the previous agreement with Roche, this new agreement with Actavis adds to Scil Proteins’ portfolio of contract development and manufacturing clients. Previous customers have included global pharma companies such as Pfizer, Novartis, Sanofi, Lundbeck, large biotech companies such as Austria-based Intercell as well as numerous small biotech companies.
Financial terms: Financial terms were not disclosed.
Latest news:
